Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Elicio Therapeutics, Inc.

NASDAQ: ELTX · Life Sciences · 4 alerts · CIK 1601485

Share price
$1.48Close, Nov 16
Market cap
$41.9M
Shares outstanding
28.31MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Elicio Therapeutics, Inc. filings on SEC EDGAR ↗

4:17 PM ET 8-K
Financial Results

Elicio Therapeutics Financial Results

Elicio Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided updates on its camupepimut clinical program. The company highlighted Phase 2 AMPLIFY-7P data in pancreatic cancer showing a 49% reduction in risk of recurrence or death in ctDNA-negative patients, which will inform its Phase 3 strategy.

“We are excited by the new Phase 2 AMPLIFY-7P findings in adjuvant PDAC, which provide encouraging direction and important insights as we advance camupepimut toward late-stage development and refine our Phase 3 strategy in adjuvant PDAC.”

Robert Connelly, President and Chief Executive Officer

“The 49% lower risk of disease recurrence or death among patients with undetectable ctDNA at baseline, alongside a 43% reduction in risk among ctDNA-positive patients, reinforces the encouraging clinical activity observed across both subgroups.”

Robert Connelly, President and Chief Executive Officer
4:17 PM ET 10-Q
Financial Results

Elicio Therapeutics Q3 2026 Results: Net Loss of $7.98M, Loss Narrows

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing camupepimut (ELI-002 7P) for adjuvant PDAC and other mKRAS-driven cancers. As of November 3, 2026, the company had 28,307,225 shares of common stock outstanding and is classified as a smaller reporting company and emerging growth company.

Key figure
Net loss $7.98M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.